Transforming
Non-Invasive Medical Diagnostics

Bio-RFID™

Proprietary non-invasive diagnostic technology platform that uses radio waves to identify and measure what is going on inside your body.

Form Factor
Agnostic

A technology platform that can be integrated into a variety of wearable, mobile or bench-top form factors.

100+ Potential Applications

Bio-RFID sensors can identify different molecules in the body, such as glucose, oxygen, alcohol and metabolized drugs.

Pain-free

No needles nor invasive transmitters in your body, making Bio-RFID sensors convenient and pain-free.

No Consumables

Expensive supplies, such as test strips and lancets, are not required to operate Bio-RFID devices.

“The holy grail of the medical industry and patient care.”

James H Anderson Jr., MD, FFPM, FACE
Chief Medical Officer, Know L:abs
Former Senior Medical Director, Diabetes and CardioMetabolic Medicine, Eli Lilly and Company

PRODUCTS

Know Labs is developing a family of products that can non-invasively identify and measure molecules in your body.

Blood glucose is our first priority. By applying Bio-RFID to non-invasively measure blood glucose, Know Labs can improve how 2 billion people with diabetes and pre-diabetes manage their conditions.

KL_KNOWU_PRODUCT_MOBILE.png

KnowU
On-demand and On-the-go

Place your palm or hold detachable portion for a spot reading of glucose concentration in mg/dL.

KL_UBAND (1).png

UBand
Continuous and Wearable

Put it on your wrist and forget it.
Check your glucose concentration 
through your Know Labs app.

Know Labs is committed to making a difference in the lives of millions of people around the world.

Global Innovator

Leading IP portfolio in the Radio Frequency Spectroscopy space.

Medical Grade Devices

Medical-grade devices with high level of accuracy and seeking FDA clearance.

Affordable Solutions

Expected to be three to five times less expensive than current options.

Internal Trial - September 2022

Internal Trial - September 2022

September 2, 2022

Know Labs Provides Update on IRB-Approved Internal Trial of 
Non-Invasive Glucose Monitoring Technology

August 3, 2022

Know Labs Files S-1 for

New Share Offering,

Seeks Uplist to NYSE

American Exchange